Roquinimex
(Synonyms: 罗喹美克,Linomide; FCF89; ABR212616) 目录号 : GC37555
An immunomodulator with diverse biological activities
Cas No.:84088-42-6
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Roquinimex is an immunomodulator with diverse biological activities.1,2,3,4 In vivo, roquinimex (80 mg/kg) increases the number of myocardial MHC class II-expressing cells, the ratio of cytotoxic to helper T cells, and survival and decreases necrotic lesion area in a mouse model of murine coxsackievirus B3-induced myocarditis.1 It induces IFN-γ production, reduces TNF-α and IL-1β production, prevents the development of proteinuria, and ameliorates nephritis in a mouse model of chronic graft versus host disease (GVHD).2 Roquinimex (300 mg/kg) decreases colonic myeloperoxidase (MPO) activity and mucosal damage in a mouse model of colitis induced by dextran sulfate .3 It also decreases tumor weight and tumor blood flow in a von Hippel-Lindau (VHL) type 2a paraganglioma mouse xenograft model.4
1.Ilb?ck, N.G., Fohlman, J., Slorach, S., et al.Effects of the immunomodulator LS 2616 on lymphocyte subpopulations in murine coxsackievirus B3 myocarditisJ. Immunol.142(9)3225-3228(1989) 2.Xiao, Z.-Y., Zhou, W.-X., Zhang, Y.-X., et al.Roquinimex-mediated protection effect on the development of chronic graft-versus-host disease in mice is associated with induction of Th1 cytokine production and inhibition of proinflammatory cytokine productionLife Sci.81(19-20)1403-1410(2007) 3.Liu, Q., Wang, Y., Wan, M.X., et al.Roquinimex inhibits dextran sodium sulfate-induced murine colitisInflamm. Res.52(2)64-68(2003) 4.Gross, D.J., Reibstein, I., Weiss, L., et al.The antiangiogenic agent linomide inhibits the growth rate of Von Hippel-Lindau paraganglioma xenografts to miceClin. Cancer Res.5(11)3669-3675(1999)
| Cas No. | 84088-42-6 | SDF | |
| 别名 | 罗喹美克,Linomide; FCF89; ABR212616 | ||
| Canonical SMILES | O=C(C1=C(O)C2=C(N(C)C1=O)C=CC=C2)N(C)C3=CC=CC=C3 | ||
| 分子式 | C18H16N2O3 | 分子量 | 308.33 |
| 溶解度 | DMSO: ≥ 83.3 mg/mL (270.17 mM) | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 3.2433 mL | 16.2164 mL | 32.4328 mL |
| 5 mM | 0.6487 mL | 3.2433 mL | 6.4866 mL |
| 10 mM | 0.3243 mL | 1.6216 mL | 3.2433 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Quality Control & SDS
- View current batch:
- Purity: >98.50%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet